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Abstract
Objective: To evaluate the use in practice and agreement be-
tween, two classification systems: Solano-Gallego (LEISH-
VET SYSTEM) and Canine Leishmaniasis Working Group 
(CLWG) clinical staging systems in a population of dogs with 
leishmaniasis. 
Methods: Clinicopathological data extracted from medical 
records of dogs previously diagnosed with leishmaniasis was 
evaluated using the two staging systems. Dogs that did not 
meet the criteria for classification were defined as unclassi-
fied. The agreement between the two staging methods was 
evaluated using unweighted K statistic (k) and Spearman’s 
coefficient of rank correlation (rho). Statistical significance 
was P < 0.05.
Results: Eighty dogs met the inclusion criteria. There were 3 
dogs in LEISHVET SYSTEM stage I, 52 dogs in LEISHVET 
SYSTEM stage II, 12 dogs in LEISHVET SYSTEM stage III, 6 
dogs in LEISHVET SYSTEM stage IV and 7 dogs unclassified. 
No dog was in CLWG stage A or B, 56 dogs were in CLWG 
stage C, 23 dogs in CLWG stage D and 1 dog unclassified. k 
value: 0.669, rho: 0.558, with P<0.0001.
Clinic significance: Despite the different number of clini-
cal stages between the two systems, the classification of dogs 
with or without proteinuria and renal involvement was pos-
sible with both methods. LEISHVET SYSTEM distinguishes 
among the different levels of proteinuria and serum creati-
nine concentration in the staging. CLWG system identifies a 
cut off value for these parameters only to formulate a prog-
nosis. Despite the presence of discordances, there was good 
agreement between the two systems in the staging of CanL.
Abbreviation: A/G: albumin globulin ratio; CanL: Canine 
leishmaniasis; CKD: chronic renal disease; CLWG: Canine 
Leishmaniasis Working Group; Hb: hemoglobin; Ht: hema-
tocrit; IFAT: indirect immunofluorescent antibody test; IgG: 
gamma globulin; IRIS: International Renal Interest Society; 
K: unweighted k statistics; PCR: polymerase chain reaction; 
PLT: platelet count; RBC: blood cells count; Rho: Spearman’s 
coefficient of rank correlation; SD: standard deviation
LEISHVET SYSTEM: LeishVet Study Group Classification; 
TP: serum total protein; UP/UC: protein creatinine ratio in 
urine sample 
Introduction
Canine leishmaniasis (CanL) due to Leishmania infantum is 
a life-threatening zoonotic disease with a wide distribution. 
CanL is endemic in more than 70 countries in the world. 
It is present in Europe, Africa, Asia and America [1] and is 
expanding in non-endemic regions [2-6]. Female sand flies 
from the genera Phlebotomus (Old World) are the princi-
pal vectors of Leishmania [7]. In dogs Leishmania infection 
may develop over a period of a few weeks to several months 
resulting in variable clinical presentations [7] ranging from 
subclinical/asymptomatic to full-blown disease, with a vari-
ety of laboratory findings depending on the host’s immune 
response [9]. The most common clinical signs are general-
ized lymphadenomegaly, weight loss, mucous membranes 
pallor, exfoliative dermatitis, lethargy, splenomegaly and fe-
ver [10]. Other signs are related to deposition of soluble im-
mune complexes in organs and tissues [11,12]. Because of 
this complex clinical presentation, CanL can be difficult to 
diagnose and the full clinical picture is often missed. Clini-
cal staging systems group patients according to the severity of 
their clinical presentation. These systems are widely used in 
human medicine [13,14] and aid evaluation of the efﬁcacy of 
different therapies, decisions on the most appropriate therapy 
for each patient and prognostic evaluation. Criteria used for 
classiﬁcation must be simple, with the use of uncomplicated 
diagnostic methods. There are very few studies using these 
clinical staging systems in veterinary medicine [15,16].
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In developing a clinical staging model for CanL, Solano-Galle-
go, et al. [7] reviewed and focused on several aspects of CanL 
and proposed a system of four clinical stages (I to IV and 2 
substages A and B), based on clinical signs, clinicopathologi-
cal abnormalities (with evaluation of renal function according 
to the recommendations of the International Renal Interest 
Society, IRIS), and serological status. Prognosis and appro-
priate therapy was classified according to stage. Subsequently, 
in 2010, the Canine Leishmaniasis Working Group (CLWG) 
proposed classification of dogs with positive serological tests, 
or those in which the parasite had been identified via direct 
diagnostic methods, into 4 stages (A to D), including, unlike 
the previous system, asymptomatic dogs as well as those with 
clinical signs [8]. The proposed classification system divided 
dogs into groups of: exposed, infected, sick and severely sick 
dogs, with only two stages for dogs with clinically evident 
leishmaniasis. In 2013 the CLWG reviewed the classification 
adding stage E for dogs unresponsive to treatment or dogs 
with early relapse and used the staging system to formulate 
a prognosis and monitor subjects depending on the stage of 
disease [17]. The purpose of this study was to evaluate practi-
cal application of the LEISHVET SYSTEM [10] clinical staging 
system and the CLWG [8] classification system in a population 
of dogs affected by canine leishmaniasis, evaluating the agree-
ment between these two schemes for the assessment of severity 
of CanL.
Materials and Methods
Study population. This study was a retrospective analysis of all 
dogs diagnosed with leishmaniasis and admitted to the Faculty 
of Veterinary Medicine University of Milan between 2000 and 
2014. The following inclusion criteria were used:
a) A complete physical examination with a detailed de-
scription of signs referable to CanL at the time of diagnosis, as 
previously reported in the literature [10].
b) A diagnosis of leishmaniasis established by clinico-
pathological abnormalities, positive serology for Leishmania 
infantum using IFAT and cytological identification of Leish-
mania amastigotes or detection of parasite DNA using poly-
merase chain reaction (PCR) in either lymph node or bone 
marrow aspirate, as previously described [18].
All dogs in which concomitant infectious diseases (e.g. babe-
siosis, ehrlichiosis, and dirofilariasis) were diagnosed by para-
sitological or/and serological examinations were excluded, 
while concomitant neoplastic, endocrine and metabolic dis-
eases were considered as described in stage D of CLWG classi-
fication. Subjects with incomplete information in the medical 
records were also excluded from the study.
Medical Records Review. Information extracted from the 
medical records of each dog with CanL comprised breed, sex, 
age, environmental history (to identify habitation or travel 
in endemic areas), clinical signs of CanL as classified in the 
literature [10], IFAT titer, cytological identification or PCR 
detection of Leishmania and laboratory findings [red blood 
cells count (RBC), hematocrit (Ht), hemoglobin (Hb), platelet 
count (PLT), serum total protein (TP), gamma globulin (IgG), 
albumin globulin ratio (A/G), creatinine serum concentration
(Serum creatinine concentration was considered non patho-
logical until 1,4 mg/dl [7]) and protein creatinine ratio in 
urine sample (UP/UC). Dogs were considered: non proteinu-
ric when UP/UC value was less than 0.5 and proteinuric when 
UP/UC value was more than 0.5 and marked proteinuric when 
UP/UC value was more than 5 [7].
All dogs were retrospectively staged using the two staging sys-
tems, i.e. LEISHVET SYSTEM [10] and CLWG [17].
Statistical analysis. All statistical analyses were performed us-
ing commercial statistical software (MedCalc, v. 15.0.0, Mari-
akerke, Belgium). Descriptive statistics were used for demo-
graphic variables. Mean, standard deviation, median, lowest 
value and highest value of RBC, Ht, Hb, PLT, TP, IgG, A/G, 
serum creatinine and UP/UC were calculated after calculating 
normal distribution of data using D’Agostino-Pearson test. The 
agreement between the LEISHVET SYSTEM and the CLWG 
staging methods was evaluated using unweighted K statistic 
(k) with a 95% confidence interval. As the two staging sys-
tems did not have the same number of clinical stages (4 for the 
LEISHVET SYSTEM and 2 for CLWG) the two staging scales 
were adapted to calculate kappa as a measure of agreement, 
recording CanL severity in 3 categories. In the LEISHVET 
SYSTEM system stages I and II received the value 1, stages III 
and IV received the value 2 and unclassified dogs received the 
value 0 (Table 1). In the CLWG system stage C received the 
value 1, stage D received the value 2 and unclassified dogs re-
ceived the value 0 (Table 2). The level of agreement was scored 
according to the following guidelines: 0: no better than chance; 
<0.20: poor agreement; 0.21–0.40: fair agreement; 0.41–0.60: 
moderate agreement; 0.61 0.80: good agreement; 0.81–1.00: 
very good agreement [19]. Spearman’s coefficient of rank cor-
relation (rho) was also used to determine the agreement of two 
methods. Statistical significance was set as P < 0.05. 
Results
The medical records of 134 dogs with CanL were reviewed, 
and 54 dogs were excluded. There were incomplete data for 
evaluation in 38 dogs, and 16 dogs had concomitant infectious 
diseases. Therefore a total of 80/134 dogs met the criteria for 
inclusion in the study. Of the 80 cases enrolled, 48 dogs (60%) 
were male (7 castrated) and 32 (40%) were female (18 spayed) 
and the mean age was 5.5years (range 7 months to 16 years). 
Thirty-two dogs were mixed breeds, 7 Setters, 6 Hounds, 4 
German Shepherds, 4 Boxer, 4 Terriers, 3 Retrievers, 3 Span-
iels, 3 Great Danes, 3 Bulldogs and the remaining 11 dogs were 
pure breeds representing 10 different breeds. All dogs origi-
nated from, or had previously travelled to, areas where CanL is 
endemic. Six dogs (7.5%) had concurrent diseases: 2 dogs had 
testicular neoplasia, 1 dog had a chemodectoma, 1 dog had a 
cutaneous plasmocytoma and 2 dogs had hyperadrenocorti-
cism. The IFAT titer ranged from 1:80 to 1: 10240. Eight dogs 
had IFAT titer 1:80, 9 dogs 1:160, 18 dogs 1:320, 23 dogs 1: 640, 
14 dogs 1:1280, 6 dogs 1:2560, 1 dog 1:5120 and 1 dog 1:10240.
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Clinical stage Serology Clinical signs Laboratory findings Category for k test
I, mild disease Negative to lowa posi-
tive antibody levels
Mild clinical signs such 
as peripheral lymphad-
enopathy, or papular 
dermatitis
No clinicopathological 
abnormalities
1
II, moderate disease Low to highb positive 
antibody levels
Dogs, with signs of 
stage I, may present: dif-
fuse or symmetrical cu-
taneous lesions such as 
exfoliative dermatitis/
onicogryphosis, ulcera-
tions, anorexia, weight 
loss, fever, epistaxis
Clinicopathological 
abnormalities such as: 
mild non-regenerative 
anemia, hypergammo-
globuminemia, hypoal-
buminemia, serum hy-
perviscosity syndrome. 
Substage A: creatinine 
<1.4 mg/dl, UP/UC<0.5
Substage B: creati-
nine <1.4 mg/dl, UP/
UC=0.5-1
1
III, severe disease Medium to high posi-
tive antibody levels
Dogs, with signs of 
stage II, may present 
signs originating from 
immune-complex le-
sions: vasculitis, arthri-
tis, uveitis and glomer-
ulonephritis
Clinicopathological 
abnormalities listed in 
stage II, chronic renal 
disease IRIS stage I with 
UP/UC >1 or IRIS stage 
II (creatinine 1.4-2 mg/
dl)
2
IV, very severe disease Medium to high posi-
tive antibody levels
Dogs with signs of stage 
III, may present with 
Pulmonary thrombo-
embolism, or nephrotic 
syndrome and end stage 
renal disease
Clinicopathological 
abnormalities listed in 
stage II, chronic renal 
disease IRIS stage III 
(creatinine 2-5 mg/dl) 
or IRIS stage IV (creati-
nine >5 mg/dl); marked 
proteinuria UP/UC >5
2
Table 1: Clinical stage, serology, clinical signs and laboratory findings of LeishVet staging system (Solano-Gallego et al. 2009) with 
category assigned for k statistic.
a dogs with negative to medium positive antibody levels should be confirmed as infected using other diagnostic techniques such as 
cytology, histology/immunohistochemistry and PCR
b high levels are defined as three-four fold increase above a well-established laboratory reference cut-off
3
.
Stage and definition Diagnostic methods 
results
Clinical signs Laboratory findings Category for k test
A, exposed Low positive antibody 
levels and negative 
cytology, histology or 
PCR
Clinically normal dogs 
or with signs associated 
with other diseases
No clinicopathological 
abnormalities
-
B, infected Low positive antibody 
levels with positive 
cytology, histology or 
PCR
Clinically normal dogs 
or with signs associated 
with other diseases
No clinicopathological 
abnormalities
-
C, sick Higha positive anti-
body levels or low level 
with positive cytology, 
histology or PCR
Clinical signs associ-
ated with leishmaniasis
Clinicopathological 
abnormalities sugges-
tive of leishmaniasis
1
D, severely sick - Signs of chronic renal 
failure (IRIS stage III 
or IV) or proteinuric 
nephropathy; severe 
ocular disease or severe 
joint disease and/
or require immuno-
suppressive therapy; 
important concomitant 
conditions, including 
neoplastic, endocrine 
or metabolic diseases
Clinicopathological 
abnormalities sugges-
tive of leishmaniasis
2
E, unresponsive to 
treatment or early 
relapse
- Clinically unresponsive 
to recommended treat-
ment – clinical relapse 
soon after cessation of 
recommended treat-
ment
- -
Table 2: Staging of Canine Leishmaniasis Working Group (Paltrinieri et al. 2010, Roura et al. 2013) with category assigned for k 
statistic.
ahigh levels are defined as ≥ four fold increase of laboratory reference value
The most common clinical signs in the 80 dogs with CanL were: 
peripheral lymphadenopathy (61 dogs, 76%), exfoliative der-
matitis (53 dogs, 66%), weight loss (21 dogs, 26%), ulcerative 
dermatitis (13 dogs, 16%), anorexia (12 dogs, 15%), polyuria 
and polydipsia (9 dogs, 11%). The most common clinicopatho-
logical abnormalities were: hypergammaglobulinemia (80 dogs, 
100%), hypoalbuminemia (76 dogs, 95%), anemia (54 dogs, 
68%), elevation of UP/UC (30 dogs, 38%) and elevation of se-
rum creatinine (19 dogs, 24%).
Table 3 shows the lowest value, highest value, mean, median, 
and standard deviation (SD) of laboratory findings. All data 
were normally distributed except for serum creatinine, UP/UC 
and IgG. The data from the dogs was categorized using the two 
staging systems and results are reported in table 2 and table 3, 
respectively. Dogs that did not meet the criteria for classification 
of one or both staging systems were defined as “unclassified”.
         
There were 3 dogs in LEISHVET SYSTEM stage I, 52 dogs in 
LEISHVET SYSTEM stage II of which 41 dogs in substage A 
and 11 dogs in substage B, 12 dogs in LEISHVET SYSTEM 
stage III, 6 dogs in LEISHVET SYSTEM stage IV and 7 dogs 
were unclassified, Three of  7 unclassified dogs had severe clin-
ical signs due to immune-complex lesions (uveitis and arthri-
tis) indicating stage III, but no laboratory findings of chronic 
kidney disease, 3/7 dogs had high positive antibody titers (four 
fold increase above established laboratory reference), but no, 
or only mild, clinical signs, 1/7 dog had severe clinical and 
laboratory abnormalities, but low antibody titers. No dog was 
in CLWG stage A and B, 56 dogs were in CLWG stage C, 23 
dogs in CLWG stage D and only 1 dog unclassified (with a 
very high specific antibody titer, but no clinical signs nor clinic 
pathological abnormalities compatible with CanL).
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Parameter Minimum value Maximum value Mean Median SD Laboratory ref-
erence range
RBC (103/µL) 1880 7600 5350 5500 ± 1150 5700-8800
Ht (%) 12 48.6 33.27 34.5 ± 7.88 37-57
Hb (g/dl) 4.2 17.8 12.20 12.8 ± 2.82 12.9-18.4
PLT (103/µL) 37 614 256.65 263 ± 106.14 143-400
TP (g/dl) 5.5 12.1 8.30 8.2 ± 1.42 6-8
Albuminemia 
(%)
7 56 32.77 33 ± 11.06 46.3-58.5
IgG (%) 8.4 76 31.73 27.84 ± 16.83 5.3-9.9
A/G 0.08 1.32 0.53 0.5 ± 0.26 0.8-1.7
Serum creati-
nine (mg/dl)
0.3 6.1 1.19 0.9 ± 0.88 < 1.2
UP/UC 0 6.6 0.83 0.3 ± 1.3322 < 0.5
Table 3: Lowest value, highest value, mean, median value and standard deviation of laboratory findings included in the study.
LeishVet system
CLWG system Dogs in Stage I Dogs in Stage II Dogs in Stage III Dogs in Stage 
IV
Un c l a s s i f i e d 
dogs
TOTAL
Dogs in Stage C 3 48 1 1 3 56
Dogs in Stage D 0 4 11 5 3 23
Un c l a s s i f i e d 
dogs
0 0 0 0 1 1
TOTAL 3 52 12 6 7 80
Table 4: Distribution of 80 dogs with CanL according to the 4 different clinical stages identified by SG staging system and the 2 
clinical stage identified by CLWG staging system.
Six of 23 dogs categorized as D stage were included in this stage 
as a result of a concomitant severe condition (4 for neoplasia 
and 2 for hypradrenocorticism). Table 4 illustrates the conflict-
ing results of dogs classified differently by the two staging sys-
tems.
In the reformulated categories used to calculate kappa as a 
measure of agreement of the between the LEISHVET SYSTEM 
and CWLG systems respectively, 55 dogs and 56 dogs received 
value 1, 18 dogs and 23 dogs received value 2 and 7 dogs and 
only 1 dog value 0. Unweighted K statistics demonstrated a k 
value of 0.669 (95% CI 0.510 to 0.827) with good agreement 
in the assessment of CanL stage between LEISHVET SYSTEM 
and CLWG systems. Spearman’s coefficient of rank correlation 
(rho) between the LEISHVET SYSTEM and CLWG systems 
was 0.558 (95% CI 0.386 to 0.693), with a level of significance 
of P<0.0001.
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Discussion
Clinical staging systems are very important in clinically com-
plex and evolving diseases such as leishmaniasis, as they can 
contribute to prognostic information as well as to plans for 
therapeutic management of affected dogs [7]. To categorize 
patient’s clinicians should be able to use a rapid, simple stag-
ing system to stage disease and to guide therapy. A validated 
method for clinical staging for CanL would aid comparison 
of different treatment protocols presented in the literature, 
the evaluation of potential side effects and would simplify the 
calculation of the most important prognostic factors. To the 
authors’ knowledge this is the first time that 2 clinical stag-
ing systems for CanL, the LEISHVET SYSTEM and the CLWG 
systems, have been compared. We also evaluated the clinical 
application of these methods in a population of dogs with 
CanL in a non-endemic area and the agreement between the 
classifications for disease severity.
Both staging systems were found to be applicable to our het-
erogeneous population of dogs with CanL. Most dogs were 
easily classified in stage II of “moderate disease” in the LEISH-
VET SYSTEM system (41 dogs) and in stage C of “sick” in the 
CLWG system (56 dogs).
Despite the fact the CLWG dedicates only two clinical stages to 
the sick subjects and LEISHVET SYSTEM has 4 clinical stages 
and two sub stages with detailed definition of creatinine serum 
concentration and proteinuria according to IRIS classification, 
the classification of dogs with or without proteinuria and re-
nal involvement was simple with both systems. During CanL, 
one of the most important factor-influencing prognosis is the 
severity of any renal damage [10], so a precise categorization 
of clinical cases allows a more focused evaluation of therapeu-
tic and prognostic factors [7]. LEISVET SYSTEM records the 
degree of proteinuria in each stage, and this makes the practi-
cal application of the score system slightly stiff. During CanL 
monitoring UP/UC value is very important because protein-
uria is an early indicator of renal involvement often presents 
in the absence of an alteration in serum creatinine [18]. Fur-
thermore quantitative measurement of proteinuria plays also a 
major role in the follow-up during treatment [7,20,21]. CLWG 
on the other end, affects the prognosis of the ill dogs as “fa-
vourable” or “guarded”, depending on the serum creatinine 
concentration and proteinuria value. This data provides to the 
practitioner an objective tool to communicate with the owner.
Using the LEISHVET SYSTEM 7 dogs could not be classified, 
mainly because of discrepancies between the antibody titer 
and clinical signs. The LEISHVET SYSTEM classification sys-
tem allocates medium to high titers in the latter stages of the 
disease and low or negative titers in mild or moderate stages. 
Although the LEISHVET SYSTEM, provides detailed classifi-
cation of leishmaniotic dogs, it has the limitation of not allow-
ing classification of dogs without a direct correlation between 
IFAT titer and clinical signs [18]. In this study there were 3 
dogs with high antibody levels, but few or no clinical signs, and 
one dog with severe clinical signs (eg asthenia, anemia), but 
low antibody titers. Three other cases had clinical abnormali-
ties caused by immune complex deposition in eyes or joints as 
required for stage III, but they did not have renal abnormalities 
in laboratory parameters, as required by the LEISHVET SYS-
TEM to allocate them in stage III. Many of the clinical mani-
festations of CanL are related with host immune response and 
are associated with deposition of soluble immune complexes 
in tissues [7]. Several studies have described the levels of Leish-
mania IgG in sick, asymptomatic, and treated dogs, sometimes 
with conflicting results [18,12,22,23]. The varying immune re-
sponse of affected animals with different clinical presentations 
makes the precise classification of clinical cases sometimes 
difficult and could explain the presence of “unclassified” dogs 
with the LEISHVET SYSTEM.
Staging of clinical cases with CLWG is less detailed and sche-
matic, so that it is easier to allocate ill dogs in different stages. 
In fact the definition of “sick dog”, allows inclusion of dogs 
with significant clinical signs or laboratory abnormalities re-
gardless of serology. These features allow the clinician to ap-
ply the CLWG staging system even in presence of conflicting 
results. In this study, only one case could not be classified using 
the CLWG system: this dog had a high IFAT titer (1: 5120), but 
no clinical or laboratory abnormalities, (as required for stage 
C of sick animal). Unlike LEISHVET SYSTEM, CLWG system 
does not distinguish among the levels above the normal value 
of proteinuria and serum creatinine concentration in the stag-
ing but identifies a cut off value for these parameters only to 
formulate a prognosis.
Despite the different clinical approach, there was good agree-
ment between the two classification systems (k = 0.669) with 
a significant level of association (P <0.0001), supporting the 
clinical use of both systems in the staging of CanL. The com-
parison of two or more staging systems is widely used in hu-
man medicine to assess their effectiveness and to select the 
most comprehensive and reliable system [14,24]. As in this 
study the comparison of staging systems with many differ-
ent stages is complex [13,25] and it may be difficult to define 
the best classification system, rather advantageous features 
are identified in each evaluated system [14]. As most cases of 
CanL are diagnosed and treated by veterinary practitioners, 
the main purpose of this study was to evaluate whether there 
were difficulties with the application of the two staging systems 
in clinical practice. A possible limitation of our study is the 
case history load, which was typical of a non-endemic area, 
with the majority of dogs with mild or moderate disease. This, 
unfortunately, allowed only a precise evaluation of LEISHVET 
SYSTEM stage II and CLWG stage C of classification systems. 
Another possible limitation is the decision to merge some 
clinical stages of the LEISHVET SYSTEM system to perform 
the k test. This decision was based on similar studies in human 
literature [26]. Future studies should include the assessment 
of the prognostic potential of the two staging systems, using 
survival calculations. This would require a broader review of 
medical records, beyond the time of diagnosis.
Conclusion
In conclusion, our results show that the LEISHVET SYSTEM 
clinical staging system and the CLWG staging system are sim-
ple and clinically useful methods for classifying dogs with 
CanL, and that there was a good agreement between the two 
systems. LEISHVET SYSTEM has 4 clinical stages and two 
sub stages with detailed definition of creatinine serum con-
centration and proteinuria according to IRIS classification. 
Its correlation of antibody titer and clinical symptoms/clin-
icopathological abnormalities for each stage make difficult to 
classifying a larger number of dogs than with CLWG system. 
CLWG system does not distinguish among the different levels 
of proteinuria and serum creatinine concentration in the stag-
ing but identifies a cut off value for these parameters only to 
formulate a prognosis. CLWG is less detailed and schematic 
than LEISHVET SYSTEM, so that it is easier to allocate the 
cases in different stages.
6
  Clerisy Publishers         
 
                J Vet Clin Pract Pet Care  2016 | Vol 1: 103
7  Clerisy Publishers         
 
                  J Vet Clin Pract Pet Care  2016 | Vol 1: 103
5) Petersen CA, Barr SC (2009) Canine leishmaniasis in North 
America: emerging or newly recognized? Vet Clin North Am 
Small Anim Pract 39: 1065-1074.
6) Shaw SE, Langton DA, Hillman TJ (2009) Canine leish-
maniosis in the United Kingdom: a zoonotic disease waiting 
for a vector? Vet Parasitol 163: 281-285.
7) Solano-Gallego L, Koutinas A, Miró G, Cardoso L, Pennisi 
MG (2009) Directions for the diagnosis, clinical staging, treat-
ment and prevention of canine leishmaniosis. Vet Parasitol 
165: 1-18.
8) Paltrinieri S, Solano-Gallego L, Fondati A, Lubas G, Gra-
doni L, Castagnaro M, et al. (2010) Guidelines for diagnosis 
and clinical classification of leishmaniasis in dogs. J Am Vet 
Med Assoc 236: 1184-1191.
9) Reis AB, Martins-Filho OA, Teixeira-Carvalho A, Giun-
chetti RC, Carneiro CM, et al. (2009) Systemic and compart-
mentalized immune response in canine visceral leishmaniasis. 
Vet Immunol Immunopathol 128: 87-95.
10) Solano-Gallego L, Miró G, Koutinas A, Cardoso L, Pennisi 
MG, et al. (2011) LeishVet guidelines for the practical manage-
ment of canine leishmaniosis. Parasit Vectors 4: 86.
References
1) Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Fer-
rer L (2008) Canine leishmaniosis - new concepts and insights 
on an expanding zoonosis: part one. Trends Parasitol 24: 324-
330.
2) Amusategui I, Sainz A, Aguirre E, Tesouro MA (2004) Se-
roprevalence of Leishmania infantum in northwestern Spain, 
an area traditionally considered free of leishmaniasis. Ann N 
Y Acad Sci 1026: 154-157.
3) Maroli M, Rossi L, Baldelli R, Capelli G, Ferroglio E, 
Genchi C, et al. (2008) The northward spread of leishmaniasis 
in Italy: evidence from retrospective and ongoing studies on 
the canine reservoir and phlebotomine vectors. Trop Med Int 
Health 13: 256-264.
4) Menn B, Lorentz S, Naucke TJ  (2010) Imported and travel-
ling dogs as carriers of canine vector-borne pathogens in Ger-
many. Parasit Vectors 3: 34.
11) Almeida MA, Jesus EE, Sousa-Atta ML, Alves LC, Berne 
ME (2005) Antileishmanial antibody profile in dogs naturally 
infected with Leishmania chagasi. Vet Immunol Immuno-
pathol 106: 151-158.
12)  de Freitas JC, Lopes-Neto BE, de Abreu CR, Coura-Vital 
W, Braga SL, et al. (2012) Profile of anti-Leishmania antibodies 
related to clinical picture in canine visceral leishmaniasis. Res 
Vet Sci 93: 705-709.
13) Bbbas ZG, Lutale JK, Game FL, Jeffcoate WJ (2008) Com-
parison of four systems of classification of diabetic foot ulcers 
in Tanzania. Diabet Med 25: 134-137.
14) Sirivatanauksorn Y, Tovikkai C (2011) Comparison of 
staging systems of hepatocellular carcinoma. HPB Surg 2011: 
818217
15) Polton GA, Brearley MJ (2007) Clinical stage, therapy, and 
prognosis in canine anal sac gland carcinoma. J Vet Intern 
Med 21: 274-280
16) López-Alvarez J, Elliott J, Pfeiffer D, Chang YM, Mattin 
M, et al. (2015) Clinical severity score system in dogs with de-
generative mitral valve disease. J Vet Intern Med 29: 575-581.
17) Roura X, Fondati A, Lubas G, Gradoni L, Maroli M, et al. 
(2013) Prognosis and monitoring of leishmaniasis in dogs: a 
working group report. Vet J 198: 43-47.
18) Proverbio D, Spada E, Bagnagatti de Giorgi G, Perego R, 
Valena E (2014) Relationship between Leishmania IFAT titer 
and clinicopathological manifestations (clinical score) in dogs. 
Biomed Res Int 2014: 412808.
19) Landis JR, Koch GG (1977) The measurement of observer 
agreement for categorical data. Biometrics 33: 159-174.
20) Pierantozzi M, Roura X, Paltrinieri S, Poggi M, Zatelli 
A (2013) Variation of proteinuria in dogs with leishmaniasis 
treated with meglumine antimoniate and allopurinol: a retro-
spective study. J Am Anim Hosp Assoc 49: 231-236.
21) IRIS Glomerular Disease Study Group, RE Goldstein, 
chair, C. Brovida, ML Fernandez-del Palacio, MP Littman, DJ 
Polzin, et al. (2013) Consenus Recommendations for Treat-
ment for Dogs with Serology Positive Glomerular Disease. J 
Vet Intern Med 27: S60-S66.
22) Solano-Gallego L, Riera C, Roura X, Iniesta L, Gallego M, 
et al. (2001) Leishmania infantum-specific IgG, IgG1 and IgG2 
antibody responses in healthy and ill dogs from endemic areas. 
Evolution in the course of infection and after treatment. Vet 
Parasitol 96: 265-276
23) Teixeira Neto RG, Giunchetti RC, Carneiro CM, Vitor RW, 
Coura-Vital W, et al. (2010) Relationship of Leishmania-spe-
cific IgG levels and IgG avidity with parasite density and clini-
cal signs in canine leishmaniasis. Vet Parasitol 169: 248-257.
24) Parra J, Augustijn PB, Geerts Y, van Emde Boas W (2001) 
Classification of epileptic seizures: a comparison of two sys-
tems. Epilepsia 42: 476-482.
25) Nicholls D, Chater R,  Lask B (2000) Children into DSM 
don’t go: a comparison of classification systems for eating dis-
orders in childhood and early adolescence. Int J Eat Disord 28: 
317-324
26) Sprikkelman AB, Tupker RA, Burgerhof H, Schouten JP, 
Brand PL, et al. (1997) Severity scoring of atopic dermatitis: 
a comparison of three scoring systems. Allergy 52: 944-949.
27) Chen TW, Chu CM, Yu JC, Chen CJ, Chan DC, Liu YC, et 
al. (2007) Comparison of clinical staging systems in predicting 
survival of hepatocellular carcinoma patients receiving major 
or minor hepatectomy. Eur J Surg Oncol 33: 480-487
28) Corona M, Ciaramella P, Pelagalli A, Cortese L, Pero ME, 
Santoro D, et al. (2004) Haemostatic disorders in dogs natu-
rally infected by Leishmania infantum. Vet Res Commun 28 
Suppl 1: 331-334
29)Hopkins MP, Reid GC, Johnston CM, Morley GW (1992) 
A comparison of staging systems for squamous cell carcinoma 
of the vulva. Gynecol Oncol 47: 34-37.
30) Rodríguez A, Solano-Gallego L, Ojeda A, Quintana J, Ri-
era C, et al. (2006) Dynamics of Leishmania-specific immu-
noglobulin isotypes in dogs with clinical leishmaniasis before 
and after treatment. J Vet Intern Med 20: 495-498.
 
                            J Vet Clin Pract Pet Care  2016 | Vol 1: 103  Clerisy Publishers         
